LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Acquired by Invesco Ltd.

Invesco Ltd. lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 50.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 174,998 shares of the medical instruments supplier’s stock after buying an additional 58,720 shares during the period. Invesco Ltd. owned approximately 0.78% of LeMaitre Vascular worth $16,124,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. MML Investors Services LLC raised its holdings in shares of LeMaitre Vascular by 2.8% during the third quarter. MML Investors Services LLC now owns 7,107 shares of the medical instruments supplier’s stock valued at $660,000 after acquiring an additional 191 shares during the period. Barclays PLC boosted its position in LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after purchasing an additional 29,180 shares during the period. Geode Capital Management LLC raised its holdings in LeMaitre Vascular by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock worth $50,403,000 after acquiring an additional 23,443 shares during the period. Sanctuary Advisors LLC bought a new position in shares of LeMaitre Vascular in the third quarter worth about $181,000. Finally, Franklin Resources Inc. lifted its holdings in shares of LeMaitre Vascular by 5.2% during the third quarter. Franklin Resources Inc. now owns 12,646 shares of the medical instruments supplier’s stock worth $1,165,000 after buying an additional 627 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Activity

In related news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.79% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Lake Street Capital raised their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Finally, Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average target price of $95.25.

LeMaitre Vascular Trading Up 1.9 %

LMAT stock opened at $86.28 on Monday. LeMaitre Vascular, Inc. has a 1-year low of $62.40 and a 1-year high of $109.58. The firm has a market cap of $1.95 billion, a PE ratio of 47.15, a P/E/G ratio of 2.22 and a beta of 0.89. The business’s 50-day moving average price is $87.85 and its two-hundred day moving average price is $93.52.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.49. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. On average, analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a dividend of $0.20 per share. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date was Thursday, March 13th. This represents a $0.80 annualized dividend and a yield of 0.93%. LeMaitre Vascular’s dividend payout ratio is presently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.